FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2284656480> ?p ?o ?g. }

• W2284656480 endingPage "1613" @default.
• W2284656480 startingPage "1607" @default.
• W2284656480 abstract "We evaluated the impact of patient selection and treatment strategies on long-term outcomes of patients who had lobectomy after induction therapy for stage IIIA pN2 non-small cell lung cancer (NSCLC). The impact of various patient selection, induction therapy and operative strategies on survival of patients with biopsy-proven stage IIIA pN2 NSCLC who received induction chemotherapy ± radiation followed by lobectomy from 1995 to 2012 was assessed using Cox proportional hazards analysis. From 1995 to 2012, 111 patients had lobectomy for stage IIIA pN2 NSCLC after chemotherapy ± radiation with an overall 5-year survival of 39%. The use of induction chemoradiation decreased over time; from 1996 to 2007, 46/65 (71%) patients underwent induction chemoradiation, whereas from 2007 to 2012, 36/46 (78%) patients underwent induction chemotherapy. The use of video-assisted thoracoscopic surgery (VATS) increased over the time period of the study, from 0/26 (0%) in 1996–2001, to 4/39 (10%) in 2002–07 to 33/46 (72%) in 2008–12. Compared with patients given induction chemotherapy alone, patients given additional induction radiation were more likely to have complete pathologic response (30 vs 11%, P = 0.01) but had worse 5-year survival in univariable analysis (31 vs 48%, log-rank P = 0.021). Patients who underwent pathologic mediastinal restaging following induction therapy but prior to resection had an improved overall survival compared with patients who did not undergo pathologic mediastinal restaging {5-year survival: 45.2 [95% confidence interval (CI): 33.9–55.9] vs 13.9% (95% CI: 2.5–34.7); log-rank, P = 0.004}. In multivariable analysis, the particular induction therapy strategy and the surgical approach used, as well as the extent of mediastinal disease were not important predictors of survival. However, pathologic mediastinal restaging was associated with improved survival (HR 0.39; 95% CI: 0.21–0.72; P = 0.003). For patients with stage IIIA pN2 NSCLC, the VATS approach or the addition of radiation to induction therapy can be selectively employed without compromising survival. The strategy of assessing response to induction therapy with pathologic mediastinal restaging allows one to select appropriate patients for complete resection and is associated with a 5-year overall survival of 39% in this population." @default.
• W2284656480 created "2016-06-24" @default.
• W2284656480 creator A5001948668 @default.
• W2284656480 creator A5003085442 @default.
• W2284656480 creator A5009068724 @default.
• W2284656480 creator A5017614420 @default.
• W2284656480 creator A5017908122 @default.
• W2284656480 creator A5026301572 @default.
• W2284656480 creator A5045174120 @default.
• W2284656480 creator A5056277456 @default.
• W2284656480 creator A5069896528 @default.
• W2284656480 creator A5072825952 @default.
• W2284656480 creator A5085912441 @default.
• W2284656480 date "2015-12-30" @default.
• W2284656480 modified "2023-10-17" @default.
• W2284656480 title "Impact of patient selection and treatment strategies on outcomes after lobectomy for biopsy-proven stage IIIA pN2 non-small cell lung cancer" @default.
• W2284656480 cites W1623635612 @default.
• W2284656480 cites W1842558207 @default.
• W2284656480 cites W1954745527 @default.
• W2284656480 cites W1962989085 @default.
• W2284656480 cites W1971494695 @default.
• W2284656480 cites W1973351412 @default.
• W2284656480 cites W2013415917 @default.
• W2284656480 cites W2014013449 @default.
• W2284656480 cites W2022554983 @default.
• W2284656480 cites W2023489612 @default.
• W2284656480 cites W2039454516 @default.
• W2284656480 cites W2048316728 @default.
• W2284656480 cites W2055229609 @default.
• W2284656480 cites W2058529839 @default.
• W2284656480 cites W2062662021 @default.
• W2284656480 cites W2073386444 @default.
• W2284656480 cites W2078641219 @default.
• W2284656480 cites W2108075045 @default.
• W2284656480 cites W2109061552 @default.
• W2284656480 cites W2110996227 @default.
• W2284656480 cites W2131790650 @default.
• W2284656480 cites W2139980395 @default.
• W2284656480 cites W2207056015 @default.
• W2284656480 cites W2210984611 @default.
• W2284656480 doi "https://doi.org/10.1093/ejcts/ezv431" @default.
• W2284656480 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4867397" @default.
• W2284656480 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26719403" @default.
• W2284656480 hasPublicationYear "2015" @default.
• W2284656480 type Work @default.
• W2284656480 sameAs 2284656480 @default.
• W2284656480 citedByCount "26" @default.
• W2284656480 countsByYear W22846564802015 @default.
• W2284656480 countsByYear W22846564802016 @default.
• W2284656480 countsByYear W22846564802017 @default.
• W2284656480 countsByYear W22846564802018 @default.
• W2284656480 countsByYear W22846564802019 @default.
• W2284656480 countsByYear W22846564802020 @default.
• W2284656480 countsByYear W22846564802021 @default.
• W2284656480 countsByYear W22846564802023 @default.
• W2284656480 crossrefType "journal-article" @default.
• W2284656480 hasAuthorship W2284656480A5001948668 @default.
• W2284656480 hasAuthorship W2284656480A5003085442 @default.
• W2284656480 hasAuthorship W2284656480A5009068724 @default.
• W2284656480 hasAuthorship W2284656480A5017614420 @default.
• W2284656480 hasAuthorship W2284656480A5017908122 @default.
• W2284656480 hasAuthorship W2284656480A5026301572 @default.
• W2284656480 hasAuthorship W2284656480A5045174120 @default.
• W2284656480 hasAuthorship W2284656480A5056277456 @default.
• W2284656480 hasAuthorship W2284656480A5069896528 @default.
• W2284656480 hasAuthorship W2284656480A5072825952 @default.
• W2284656480 hasAuthorship W2284656480A5085912441 @default.
• W2284656480 hasBestOaLocation W22846564801 @default.
• W2284656480 hasConcept C126322002 @default.
• W2284656480 hasConcept C141071460 @default.
• W2284656480 hasConcept C143998085 @default.
• W2284656480 hasConcept C146357865 @default.
• W2284656480 hasConcept C151730666 @default.
• W2284656480 hasConcept C2775934546 @default.
• W2284656480 hasConcept C2776256026 @default.
• W2284656480 hasConcept C2776611710 @default.
• W2284656480 hasConcept C2776694085 @default.
• W2284656480 hasConcept C509974204 @default.
• W2284656480 hasConcept C71924100 @default.
• W2284656480 hasConcept C86803240 @default.
• W2284656480 hasConceptScore W2284656480C126322002 @default.
• W2284656480 hasConceptScore W2284656480C141071460 @default.
• W2284656480 hasConceptScore W2284656480C143998085 @default.
• W2284656480 hasConceptScore W2284656480C146357865 @default.
• W2284656480 hasConceptScore W2284656480C151730666 @default.
• W2284656480 hasConceptScore W2284656480C2775934546 @default.
• W2284656480 hasConceptScore W2284656480C2776256026 @default.
• W2284656480 hasConceptScore W2284656480C2776611710 @default.
• W2284656480 hasConceptScore W2284656480C2776694085 @default.
• W2284656480 hasConceptScore W2284656480C509974204 @default.
• W2284656480 hasConceptScore W2284656480C71924100 @default.
• W2284656480 hasConceptScore W2284656480C86803240 @default.
• W2284656480 hasIssue "6" @default.
• W2284656480 hasLocation W22846564801 @default.
• W2284656480 hasLocation W22846564802 @default.
• W2284656480 hasLocation W22846564803 @default.
• W2284656480 hasLocation W22846564804 @default.
• W2284656480 hasOpenAccess W2284656480 @default.

• next